I compared this Form DEF 14A with the Form PRE 14A issued

New Post Public Reply Private Reply Replies (1) Message Board
BruceLake nlightn #14334
427
I compared this Form DEF 14A with the Form PRE 14A issued on February 8. It's confirmed that the Special Meeting of Stockholders of OWC Pharmaceutical Research Corp., will take place at 10:00 a.m., on April 4, 2019.

The current filing has some additional clauses and clarified a few others. Whatever is in bold has been added. The most interesting one is the fact that they have engaged the services of a third party to solicit affirmative votes!

Page 2
3rd paragraph:
On or about February 18, 2019, this proxy statement, together with the related proxy card, is being mailed to our stockholders of record as of the Record Date. In addition, we have hired Morrow Sodali LLC, 470 West Ave., Stamford, CT 06902 to aid us in the solicitation of proxies for a fee of $7,500 plus out-of-pocket expenses.

Page 7
4th paragraph:
Material U.S. Federal Income Tax Consequences of the Reverse Stock Split
The following is a summary of the material U.S. federal income tax consequences of the reverse stock split to holders of our Common Shares that is a U.S. holder (as defined below). This summary is based on the Internal Revenue Code of 1986, as amended (the “Code”), the Treasury regulations promulgated thereunder, and administrative rulings and court decisions in effect as of the date of this document, all of which may be subject to change, possibly with retroactive effect. This summary only addresses U.S. federal tax consequences to U.S. holders who hold their shares as capital assets within the meaning of the Code. This summary does not address all aspects of U.S. federal income taxation that may be relevant to U.S. holders subject to special tax treatment, such as financial institutions, dealers in securities, insurance companies, foreign persons, tax-exempt entities, regulated investment companies, real estate investment trusts, U.S. expatriates, persons subject to the alternative minimum tax, and persons that hold our common stock as part of a position in a “straddle” or as part of a “hedging,” “conversion,” or other integrated investment transaction for federal income tax purposes. In addition, this summary does not consider the effects of any applicable state, local, foreign or other tax laws.

Added the following 2 clauses:
For purposes of this summary, a “U.S. holder” is any beneficial owner of our Common Shares that is any of the following: (a) an individual who is or is treated as a citizen or resident of the United States; (b) a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any state thereof or the District of Columbia; (c) an estate the income of which is subject to U.S. federal income taxation regardless of its source; or (d) a trust (i) if a court within the United States is able to exercise primary supervision over the administration of such trust and one or more “United States Persons” have the authority to control all substantial decisions of such trust or (ii) that has a valid election in effect to be treated as “United States Persons” for U.S. federal income tax purposes.

If a partnership (or other entity classified as a partnership for U.S. federal income tax purposes) is the beneficial owner of our common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner and the activities of the partnership. Partnerships that hold our common stock, and partners in such partnerships, should consult their own tax advisors regarding the U.S. federal income tax consequences of the reverse stock split.

Page 8
2nd clause:
A U.S. holder who receives cash in lieu of a fractional share of Common Stock will be treated as first receiving such fractional share and then receiving cash in redemption of such fractional share. A U.S. holder generally will recognize capital gain or loss on such deemed redemption in an amount equal to the difference between the amount of cash received and the adjusted basis of such fractional share. Such capital gain or loss will be a short term if the Common Stock surrendered in the reverse stock split were held for one year or less and long term if held for more than one year.

Added the following clause:
Information returns generally will be required to be filed with the IRS with respect to the receipt of cash in lieu of a fractional share of our Common Stock pursuant to the reverse stock split in the case of certain U.S. holders. In addition, U.S. holders may be subject to a backup withholding tax at the rate specified in the Code on the payment of such cash if they do not provide their taxpayer identification numbers in the manner required or otherwise fail to comply with applicable backup withholding tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the U.S. holder’s federal income tax liability, if any, provided the required information is timely furnished to the IRS.

Page 10
1st paragraph:
As of the Record Date, there were 3,054 holders of record of our Common Stock,

Added Appendix A-2
Includes voting instructions and a proxy.

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

Updated Category News Views 254

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 144

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 291

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 263

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 159

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 242

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 327

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading

Top 5 Most Recently Viewed Articles

2026 Honors Shaping Leadership Through Innovation

Updated Category News Views 52

Frost & Sullivan Institute: Leading By Example Alright, folks, we’re talking about the kind of business leadership that isn’t just about fattening the bottom line. The Frost & Sullivan Institute rolled out the carpet for companies that don’t just talk the talk—they walk the walk. This recognition isn't just another plaque for the wall; it's a pat on the back for...

Continue Reading
Boosting Franchise Performance Through Gamification with Batteries Plus

Updated Category News Views 204

Revolutionizing Franchise Excellence: The Plus Games Batteries Plus, a leader in the battery retail sector, has embarked on an exciting journey with its newly announced initiative called The Plus Games. This program is designed to transform franchisee training and sales strategies by gamifying the entire process. The objective? To cultivate exceptional performance and...

Continue Reading
Investigation into Eos Energy Enterprises' Potential Securities Fraud

Updated Category News Views 213

Investigation into Eos Energy Enterprises Pomerantz LLP is currently investigating claims concerning investors of Eos Energy Enterprises, Inc. (NASDAQ: EOSE). This inquiry raises questions about whether the company and some of its executives may have been involved in securities fraud or other fraudulent business practices. Recent Developments at Eos Energy Recently, Eos...

Continue Reading
Emerging Trends Transforming the Global Cold Brew Coffee Market

Updated Category News Views 184

Impact of Millennial Preferences on Cold Brew Coffee The cold brew coffee market is poised for significant growth, estimated to expand by USD 519.2 million within the forecast period. This growth is largely driven by changing consumer preferences, particularly among millennials who favor modern, convenient beverage choices. As more companies enter the market with...

Continue Reading
EMCOR Group, Inc. Announces Quarterly Dividend for Shareholders

Updated Category News Views 74

EMCOR Group, Inc. Announces Quarterly Cash Dividend NORWALK, Conn. - EMCOR Group, Inc. (NYSE: EME) has proudly declared a regular quarterly cash dividend of $0.25 per common share. This announcement was made by the Board of Directors, showing their ongoing commitment to delivering value to shareholders. Dividend Payment Details The scheduled payment date for the upcoming...

Continue Reading